{"answer":{"query":"lenvima","resolved_as":"name","packages":16,"applications":["NDA206947"],"identity":{"application_numbers":["NDA206947"],"marketing_categories":["NDA"],"labelers":[{"text":"EISAI INC.","untrusted":true}],"dosage_forms":[{"text":"CAPSULE","untrusted":true},{"text":"KIT","untrusted":true}],"marketing_start":{"earliest":"2015-02-13","latest":"2018-08-15","packages_with_a_start_date":8}},"generic_entry":[{"application":"NDA206947","date":"2038-11-15","reading":"upper bound from listed dates, not a forecast","basis":"latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled)","driver":{"kind":"patent","ref":"12226409*PED","productNo":"001"},"latest_patent_expiry":"2038-11-15","latest_exclusivity_expiry":"2027-10-03","dated_barriers":48,"undated_barriers":0,"orange_book_edition":"2026-09","patents_listed":10,"exclusivities_listed":4,"fact_id":"9ea61c897fb0f11b4492abac"}],"label_history":{"events_total":24,"non_cmc_events":23,"counts_by_class":{"EFFICACY":11,"LABELING":12},"cmc_events":1,"recent_non_cmc_events":[{"application":"NDA206947","submission_no":35,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2026-09-24","documents":[{"type":"Letter","date":"2026-09-28","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/206947Orig1s035ltr.pdf","untrusted":true}},{"type":"Label","date":"2026-09-28","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/206947s035lbl.pdf","untrusted":true}}],"fact_id":"566e9fead5410ba38b7bf24d"},{"application":"NDA206947","submission_no":33,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2025-01-29","documents":[{"type":"Label","date":"2025-02-05","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/206947s033lbl.pdf","untrusted":true}},{"type":"Letter","date":"2025-02-07","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/206947Orig1s033ltr.pdf","untrusted":true}}],"fact_id":"1d03cefd09ddcaf1de67cf75"},{"application":"NDA206947","submission_no":32,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2024-11-20","documents":[{"type":"Label","date":"2024-11-21","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/206947s032lbl.pdf","untrusted":true}},{"type":"Letter","date":"2024-11-21","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/206947Orig1s032ltr.pdf","untrusted":true}}],"fact_id":"fe08323e83bbada108bfc02c"},{"application":"NDA206947","submission_no":31,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2024-06-07","documents":[{"type":"Label","date":"2024-06-10","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2024/206947s031lbl.pdf","untrusted":true}},{"type":"Letter","date":"2024-07-02","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/206947Orig1s031ltr.pdf","untrusted":true}}],"fact_id":"13b7a13f2cc95e45d9928e5a"},{"application":"NDA206947","submission_no":30,"class_code":"EFFICACY","class_description":{"text":"Efficacy","untrusted":true},"status":"AP","date":"2024-04-03","documents":[{"type":"Label","date":"2024-04-03","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2024/206947s030lbl.pdf","untrusted":true}},{"type":"Letter","date":"2024-04-04","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/206947Orig1s030ltr.pdf","untrusted":true}}],"fact_id":"5b6ef8661502b64b00b4b29e"}],"note":"a dated list of FDA supplements and their classes, not a reading of what changed in the label"},"substitution":{"products_total":2,"te_code_counts":{"NOT_PROVIDED":2},"marketing_status_counts":{"Prescription":2},"meaning":"raw FDA codes; the therapeutic equivalence code says whether FDA rates a generic as substitutable, and what that means for a given prescription is for a pharmacist or prescriber","products":[{"application":"NDA206947","product_no":"001","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"LENVIMA","untrusted":true},"form":{"text":"CAPSULE;ORAL","untrusted":true},"strength":{"text":"EQ 4MG BASE","untrusted":true}},{"application":"NDA206947","product_no":"002","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"LENVIMA","untrusted":true},"form":{"text":"CAPSULE;ORAL","untrusted":true},"strength":{"text":"EQ 10MG BASE","untrusted":true}}]},"trials":{"attribution":"Source: ClinicalTrials.gov","modification_statement":"OmniRx has summarized and trimmed this ClinicalTrials.gov data.","not_an_offer":"A recruiting trial listing is not an offer of free drug and not medical advice; enrollment is decided by the study team.","ingredients":[{"ingredient":{"text":"LENVATINIB","untrusted":true},"recruiting_interventional_count":146,"not_yet_recruiting_count":82,"by_phase":{"PHASE1/PHASE2":15,"PHASE2":90,"PHASE3":17,"PHASE1":7,"EARLY_PHASE1":3,"NA":10,"PHASE4":4},"registry_processing_date":"2026-11-06T10:00:05","modifications":"Counts and phase tallies computed here from the full recruiting result set; trials trimmed to the 25 most recently updated, conditions to 3, countries to 10 distinct; no text edited.","recent_trials":[{"nct_id":"NCT06253494","title":{"text":"Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer","untrusted":true},"phase":["PHASE1","PHASE2"],"sponsor":{"text":"National Cancer Institute (NCI)","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-05","start_date":"2024-05-14","link":{"text":"https://clinicaltrials.gov/study/NCT06253494","untrusted":true}},{"nct_id":"NCT07149090","title":{"text":"Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites","untrusted":true},"phase":["PHASE1","PHASE2"],"sponsor":{"text":"Asan Medical Center","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-04","start_date":"2025-11-11","link":{"text":"https://clinicaltrials.gov/study/NCT07149090","untrusted":true}},{"nct_id":"NCT07909265","title":{"text":"Prospective Study of Cadonilimab With Lenvatinib in Renal Cell Carcinoma","untrusted":true},"phase":["PHASE2"],"sponsor":{"text":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-02","start_date":"2025-04-01","link":{"text":"https://clinicaltrials.gov/study/NCT07909265","untrusted":true}},{"nct_id":"NCT03486873","title":{"text":"Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)","untrusted":true},"phase":["PHASE3"],"sponsor":{"text":"Merck Sharp & Dohme LLC","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-10-29","start_date":"2018-08-21","link":{"text":"https://clinicaltrials.gov/study/NCT03486873","untrusted":true}},{"nct_id":"NCT07487662","title":{"text":"TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk","untrusted":true},"phase":["PHASE2"],"sponsor":{"text":"Sun Yat-sen University","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-10-27","start_date":"2026-03-20","link":{"text":"https://clinicaltrials.gov/study/NCT07487662","untrusted":true}}],"fact_id":"3538737747286614967601e5"}]},"spending":{"reported_under":{"generic":{"text":"Lenvatinib Mesylate","untrusted":true},"brand":{"text":"Lenvima","untrusted":true}},"latest_year":2024,"series":[{"year":2020,"gross_spending_usd":367767778.97,"claims":19016,"beneficiaries":4883,"average_spending_per_claim_usd":19339.912651,"fact_id":"92454fb0156137f265160c35"},{"year":2021,"gross_spending_usd":452132406.25,"claims":21961,"beneficiaries":5725,"average_spending_per_claim_usd":20587.969867,"fact_id":"80320c436dd1ed03a2cbd220"},{"year":2022,"gross_spending_usd":625976421.39,"claims":28321,"beneficiaries":7066,"average_spending_per_claim_usd":22102.906726,"fact_id":"aaee3f5c23ed6a0e6a29d64d"},{"year":2023,"gross_spending_usd":778834823.88,"claims":32513,"beneficiaries":7904,"average_spending_per_claim_usd":23954.5666,"fact_id":"da99fbd505b598ee43bf3a9d"},{"year":2024,"gross_spending_usd":875642918.93,"claims":37139,"beneficiaries":8450,"average_spending_per_claim_usd":23577.450091,"fact_id":"332cc6544cd2a4d043166689"}],"rebate_caveat":"CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions.","not_a_patient_price":"Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.","meaning":"a drug-level aggregate of Medicare Part D claims for all manufacturers combined; not a formulary, not coverage","source":{"dataset":{"text":"data-year-2024, modified 2026-06-25","untrusted":true},"link":{"text":"https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug/medicare-part-d-spending-by-drug","untrusted":true}}},"orphan_designation":{"ingredients":[{"ingredient":{"text":"lenvatinib","untrusted":true},"designation_count":5,"approved_count":2,"recent":[{"designated":"2024-11-14","use":{"text":"treatment of esophageal cancer","untrusted":true},"status":"Designated","sponsor":{"text":"Eisai Inc.","untrusted":true},"approved":false},{"designated":"2024-11-14","use":{"text":"treatment of gastric cancer, including gastroesophageal junction cancer","untrusted":true},"status":"Designated","sponsor":{"text":"Eisai Inc.","untrusted":true},"approved":false},{"designated":"2014-03-27","use":{"text":"Treatment of hepatocellular carcinoma","untrusted":true},"status":"Designated/Approved","sponsor":{"text":"Eisai Inc.","untrusted":true},"approved":true},{"designated":"2014-03-26","use":{"text":"Treatment of stage IIB to Stage IV melanoma","untrusted":true},"status":"Designated","sponsor":{"text":"Eisai, Inc.","untrusted":true},"approved":false},{"designated":"2012-12-27","use":{"text":"Treatment of follicullar, medullary, anaplastic, and metastatic or locally advanced papillary thyroid cancer","untrusted":true},"status":"Designated/Approved","sponsor":{"text":"Eisai, Inc.","untrusted":true},"approved":true}],"read_on":"2026-11-07T12:00:00.000Z","fact_id":"6a51b41b4fc08357a5ce76bc"}],"reading":"a designation is not an approval and not a statement that the drug treats the condition; status is the FDA database's own"},"medicaid_state_utilization":{"year":2025,"states_with_data":5,"all_states_medicaid_reimbursed_usd":7548102.25,"all_states_medicaid_paid_prescriptions":324,"top_states":[{"state":"CA","medicaid_paid_prescriptions":97,"medicaid_reimbursed_usd":2306659.66,"total_reimbursed_usd":2371782.22,"packages":1,"covers":"fee_for_service_only","fact_id":"caef6dd73d548d5b75ef73be"},{"state":"NC","medicaid_paid_prescriptions":66,"medicaid_reimbursed_usd":1610369.34,"total_reimbursed_usd":1610369.34,"packages":1,"covers":"fee_for_service_only","fact_id":"62378b576057e86a96d4446a"},{"state":"PA","medicaid_paid_prescriptions":54,"medicaid_reimbursed_usd":1303569.26,"total_reimbursed_usd":1303569.26,"packages":1,"covers":"fee_for_service_only","fact_id":"648c9ec03be0aeeb542be8fb"},{"state":"MI","medicaid_paid_prescriptions":49,"medicaid_reimbursed_usd":1220893.87,"total_reimbursed_usd":1220893.87,"packages":1,"covers":"all_record_types","fact_id":"369aad79ab71c32a7d088b74"},{"state":"NM","medicaid_paid_prescriptions":58,"medicaid_reimbursed_usd":1106610.12,"total_reimbursed_usd":1106610.12,"packages":1,"covers":"all_record_types","fact_id":"41eb19a32ae551e48890d970"}],"unlabelled_state_code_xx":null,"built_from_facts":5,"facts_fee_for_service_only":3,"older_year_facts_not_used":28,"dataset":"State Drug Utilization Data 2025","read_on":"2026-11-07T22:41:44.201Z","reading":"Medicaid prescriptions and reimbursement by state (CMS State Drug Utilization Data). Reimbursement is before manufacturer rebates: not a net cost, not a patient price. Suppressed managed-care cells make a state figure fee-for-service only. An absent state was suppressed or unreported, not zero.","receipts_note":"a receipt is held for the largest fact behind each state shown; every figure is a sum of the built_from_facts facts, each recomputable from its recorded input hash"}},"receipts":[{"fact_id":"b910e757daed1d7efd80c740","field":"ndc.listing","entity":"ndc:62856070430"},{"fact_id":"fea843a6341cb52a09f8ddce","field":"ndc.listing","entity":"ndc:62856070830"},{"fact_id":"1717468ac641901972482f44","field":"ndc.listing","entity":"ndc:62856071030"},{"fact_id":"9ea61c897fb0f11b4492abac","field":"drug.generic_entry_earliest","entity":"application:NDA206947"},{"fact_id":"036cf713b65c9ebda6f28980","field":"drug.patent","entity":"application:NDA206947"},{"fact_id":"7d58cc75be9ada4321e5d1b2","field":"drug.exclusivity","entity":"application:NDA206947"},{"fact_id":"566e9fead5410ba38b7bf24d","field":"drug.label_event","entity":"application:NDA206947"},{"fact_id":"1d03cefd09ddcaf1de67cf75","field":"drug.label_event","entity":"application:NDA206947"},{"fact_id":"fe08323e83bbada108bfc02c","field":"drug.label_event","entity":"application:NDA206947"},{"fact_id":"13b7a13f2cc95e45d9928e5a","field":"drug.label_event","entity":"application:NDA206947"},{"fact_id":"5b6ef8661502b64b00b4b29e","field":"drug.label_event","entity":"application:NDA206947"},{"fact_id":"ca3d9f5280d72b52c4bcfa20","field":"drug.marketing_status","entity":"application:NDA206947"},{"fact_id":"6982fa643fb83cf19115ce3b","field":"drug.marketing_status","entity":"application:NDA206947"},{"fact_id":"3538737747286614967601e5","field":"drug.trial_access","entity":"drug:lenvatinib"},{"fact_id":"92454fb0156137f265160c35","field":"drug.partd_spending","entity":"drug:lenvatinib-mesylate|lenvima"},{"fact_id":"80320c436dd1ed03a2cbd220","field":"drug.partd_spending","entity":"drug:lenvatinib-mesylate|lenvima"},{"fact_id":"aaee3f5c23ed6a0e6a29d64d","field":"drug.partd_spending","entity":"drug:lenvatinib-mesylate|lenvima"},{"fact_id":"da99fbd505b598ee43bf3a9d","field":"drug.partd_spending","entity":"drug:lenvatinib-mesylate|lenvima"},{"fact_id":"332cc6544cd2a4d043166689","field":"drug.partd_spending","entity":"drug:lenvatinib-mesylate|lenvima"},{"fact_id":"6a51b41b4fc08357a5ce76bc","field":"drug.orphan_designation","entity":"drug:lenvatinib"},{"fact_id":"caef6dd73d548d5b75ef73be","field":"ndc.medicaid_state_utilization","entity":"ndc_state:62856071230:CA"},{"fact_id":"62378b576057e86a96d4446a","field":"ndc.medicaid_state_utilization","entity":"ndc_state:62856071430:NC"},{"fact_id":"648c9ec03be0aeeb542be8fb","field":"ndc.medicaid_state_utilization","entity":"ndc_state:62856071430:PA"},{"fact_id":"369aad79ab71c32a7d088b74","field":"ndc.medicaid_state_utilization","entity":"ndc_state:62856072030:MI"},{"fact_id":"41eb19a32ae551e48890d970","field":"ndc.medicaid_state_utilization","entity":"ndc_state:62856072030:NM"}],"as_of":{"newest_fact_retrieved_at":"2026-11-10T20:02:39.475Z"},"edition":{"id":"2026-11","merkleRoot":"006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6","factCount":212100,"manifestPresent":true},"licence":{"classes":["AMBER","GREEN"],"note":"Source records are public; this compilation is cited with attribution. See the provenance tool for each fact's licence label."},"unknown":[{"code":"NO_DATA","field":"price","reason":"no NADAC price, negotiated price or federal upper limit for these packages"},{"code":"NO_DATA","field":"recalls","reason":"no FDA enforcement report naming a package of these applications is recorded"},{"code":"NO_DATA","field":"supply","reason":"no FDA shortage row and no termination date for these packages"},{"code":"NO_DATA","field":"assistance_and_offers","reason":"no assistance program lists this drug and no manufacturer offer naming it is recorded; that does not mean none exists"},{"code":"NO_DATA","field":"policy","reason":"no Federal Register event in the edition names this drug or its programs"},{"code":"NO_DATA","field":"biologic_status","reason":"no biologic application of this drug has a Purple Book status in the edition (a drug that is not a biologic has none)"},{"code":"NO_DATA","field":"payment_limit","reason":"no HCPCS code whose NDC crosswalk names a package of these applications has a Part B payment limit in the edition"},{"code":"NO_DATA","field":"rems","reason":"no REMS@FDA program is tied to these applications in the edition (most drugs have none)"},{"code":"NO_DATA","field":"controlled_schedule","reason":"no DEA schedule entry matched this drug's ingredient in the edition"},{"code":"NO_DATA","field":"safety_communication","reason":"no FDA Drug Safety Communication names this drug's ingredient in the edition"}],"disclaimer":"OmniRx is a reference layer of dated public facts, not clinical advice and not a guarantee of price, coverage or eligibility. Each answer lists the facts it rests on."}